Drug Profile


Alternative Names: AZD 2014

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cambridge University Hospitals; NHS Greater Glasgow and Clyde; University of Birmingham; University of London; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Benzamides; Cytostatics; Morpholines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Meningioma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Phase I/II Breast cancer; Fallopian tube cancer; Glioblastoma; Peritoneal cancer
  • Phase I Prostate cancer
  • No development reported Advanced breast cancer
  • Discontinued Renal cancer

Most Recent Events

  • 14 Sep 2016 AstraZeneca withdraws the modular phase I/IIa INHIBITOR trial for Diffuse large B-cell lymphoma (Second-line therapy or greater, Combination therapy) prior to enrolment in USA (PO) (NCT02780830)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Advanced-breast-cancer(Combination therapy, Metastatic disease) in USA (PO, Tablet)
  • 08 Jul 2016 AstraZeneca, United States Department of Defense and Massachusetts General Hospital plan a phase II trial for Meningioma (in patients with neurofibromatosis 2; Second-line therapy or greater) in USA (PO) (NCT02831257)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top